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Abstract
Background: Chronic fatigue syndrome (CFS) has no diagnostic clinical signs or diagnostic
laboratory abnormalities and it is unclear if it represents a single illness. The CFS research case
definition recommends stratifying subjects by co-morbid conditions, fatigue level and duration, or
functional impairment. But to date, this analysis approach has not yielded any further insight into
CFS pathogenesis. This study used the integration of peripheral blood gene expression results with
epidemiologic and clinical data to determine whether CFS is a single or heterogeneous illness.
Results: CFS subjects were grouped by several clinical and epidemiological variables thought to be
important in defining the illness. Statistical tests and cluster analysis were used to distinguish CFS
subjects and identify differentially expressed genes. These genes were identified only when CFS
subjects were grouped according to illness onset and the majority of genes were involved in
pathways of purine and pyrimidine metabolism, glycolysis, oxidative phosphorylation, and glucose
metabolism.
Conclusion: These results provide a physiologic basis that suggests CFS is a heterogeneous illness.
The differentially expressed genes imply fundamental metabolic perturbations that will be further
investigated and illustrates the power of microarray technology for furthering our understanding
CFS.
Background
Chronic fatigue syndrome (CFS) is defined solely by self-
reported symptoms and associated disability. There are no
characteristic physical signs or diagnostic laboratory
abnormalities. Diagnosis of CFS requires clinical evalua-
tion to rule out other medical or psychiatric conditions
that could cause or contribute to the patient's complaints
[1]. Indeed, it remains unclear whether CFS represents a
unique disease or a common clinical end-point of diverse
pathologic processes.
CFS has been hypothesized to involve an abnormal
response to infection, immunologic dysfunction, dysregu-
lation of the hypothalamic-pituitary-adrenal axis, and
dysautonomia, yet no biologic and physiologic perturba-
tions have been reproducibly detected. This may reflect
poor specificity of the case definition, patient selection
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laboratory markers that improve the specificity of case
ascertainment or differentiate groups within the CFS clas-
sification would increase the possibility of identifying
pathogenic mechanisms.
The international CFS research guideline recommends
that cases be stratified before analysis by several variables
including co-morbid conditions, current level and total
duration of fatigue, current level of functional impair-
ment and type of fatigue onset [1]. People with CFS often
describe a sudden onset to their illness, having become
sick over one or two days, while others recount a gradual
onset in which the symptom complex develops over
weeks or months. Studies indicate that stress history [2]
and recovery [3] appear to vary with mode of onset.
Another approach is to group subjects based on symp-
toms. A recent study identified two subgroups, one with
higher energy levels and fewer accompanying symptoms
and another with significantly lower energy levels [4].
Deciphering the physiologic basis for CFS would go far in
accessing the heterogeneity of the illness and would
advance diagnosis and treatment.
Unique gene expression profiles have been found in can-
cer [5], chronic inflammatory/allergic diseases [6,7],
autoimmune disorders (e.g., rheumatoid arthritis) [8],
and multiple sclerosis [9]. We have previously shown that
peripheral blood mononuclear cell (PBMC) gene expres-
sion profiles can distinguish the majority of CFS cases
from non-fatigued controls [10]. In this study, we meas-
ured levels of gene expression in 23 persons with CFS
identified in the general Wichita population. Our objec-
tive was to determine if integration of gene expression




This study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services. All
participants were volunteers who gave informed consent.
The Centres for Disease Control and Prevention Human
Subjects Committee approved study protocols.
Forty-three CFS subjects were identified in a survey of the
Wichita, Kansas's adult population [11]. CFS subjects ful-
filled all criteria of the CFS research case definition [1].
The clinical evaluation was used to identify any co-mor-
bid conditions and to detect the presence of exclusionary
diagnoses. These included Major Depressive Disorder
with Melancholic/Psychotic features, psychosis, alcohol/
drug addiction, bulimia/anorexia and medical conditions
including cancer, hepatitis or pregnancy. We obtained
information concerning current disability, duration of ill-
ness, type of fatigue onset, and number and nature of
accompanying symptoms. We also obtained blood sam-
ples, as described below. Because only 6 CFS subjects were
men, we limited the present study to women. Of the 37
female CFS subjects, 5 were excluded because of lack of
sample, 7 were excluded because of poor quality RNA,
and 2 were excluded because of poor quality of array
hybridization, leaving 23 women for analysis.
Table 1 lists the clinical and epidemiologic variables used
in our analysis. Onset of illness was defined as sudden
(self-reported development of fatigue in less than 1 week)
or gradual (developing fatigue over more than 1 month).
Only one woman reported that her fatigue developed
between 1 week and 1 month (Table 1) so her microarray
results were only used in cluster analysis. Age was catego-
rized as ≤50 or >50 years old, and duration of illness was
categorized as ≤10 or >10 years (grouping into different
periods did not alter the results). Body Mass Index (BMI)
was categorized as normal (≤24.9 kg/m2), overweight (25
– 29.9 kg/m2), or obese (30 – 39.9 kg/m2) [12].
Gene Expression Profiling
Nucleic acid extraction
During the clinical evaluation, a 10 ml blood sample was
obtained and PBMC were isolated using LSM® Lym-
phocyte Separation Media (ICN Biomedicals, Costa Mesa,
CA). Cells were washed, counted and stored for viability
in liquid nitrogen as described [13]. Total RNA was
extracted using the RNAqueous™ kit (Ambion Inc., Austin,
TX) and the quality and quantity were assessed as previ-
ously described [14].
Preparation and hybridization of labelled cDNA
Biotinylated cDNA synthesis from 1 µg of total RNA was
performed as previously described [14]. The cDNA probe
was hybridized to the Atlas™ Human 3.8I oligonucleotide
glass microarrays (CLONTECH Laboratories, Inc., Palo
Alto, CA) using the Ventana Discovery™ system and their
ChipMap™ kit (Ventana Medical Systems, Tucson, AZ).
Hybridization was for 12 hours at 42°C, followed by
three 10 minute stringency washes in 0.1X SSC at 42°C.
Anti-biotin antibodies conjugated to RLS™ particles (Gen-
icon Sciences Corporation, San Diego, CA) were used for
signal detection as previously described [14]. The slides
were archived and images captured using the GSD-501™
scanner (Genicon Sciences Corporation, San Diego, CA),
and analyzed with ArrayVision™ RLS image analysis soft-
ware (Genicon Sciences Corporation).
Data analysis
The scanned TIFF images were processed using ArrayVi-
sion™ (Imaging Research Inc., Ontario, Canada). Features
deemed unsuitable for accurate quantitation because of
artefacts, poor morphology, or uneven hybridization werePage 2 of 8
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value was calculated around each feature and subtracted
from the mean signal to give the net signal for the respec-
tive gene. Data was uploaded into the CDC MAdB web-
based analysis package where background-adjusted inten-
sity values were scaled and normalized to the 75th percen-
tile. Values were log2 transformed and mean centered to fit
the data to a Gaussian distribution.
We initially examined gene expression intensities for all
23 CFS subjects using the one-class analysis component of
the Significance Analysis of Microarrays (SAM) program
[15] to determine if the mean gene expression for each of
3,800 genes differed from zero. In the one-class analysis
we used false discovery rates (FDR) of up to 25%. SAM
was also used for a two-class analysis to compare the
mean differences between the gene intensity values cate-
gorised by the clinical and epidemiologic variables listed
in Table 1. An FDR of 5% was used for two-class analysis.
To identify distinct gene clusters we performed a two-way
hierarchical cluster analysis as described by Eisen et
al[16]. The dendograms were viewed using Tree View [16],
http://rana.lbl.gov/EisenSoftware.htm. All genes identi-
fied by SAM were submitted to Onto-Express (version 2)
[17]http://vortex.cs.wayne.edu:8080/index.jsp to identify
current gene ontology classifications. OntoExpress was
chosen because it interprets the probability that a particu-
lar molecular function, biological process or cellular com-
ponent occurs by chance in the context of the genes
represented on the microarray being used.
The standard statistical t-test (assuming unequal vari-
ances) and the nonparametric Wilcoxon rank sum test
were used in conjunction with the SAM two-class analysis
to examine the potential differences in gene expression
with respect to the variables outlined in Table 1. For the t-




One-class analysis of gene expression data
Application of this method to the 23 CFS subjects identi-
fied no genes with expression variance statistically greater
than the average that would provide evidence for hetero-
geneity of the CFS sample.
Table 1: Clinical and epidemiological characteristics of 23 CFS women.
Characteristic Number






Duration of illness b
≤10 15
>10 8











a Onset type defined as sudden (self-reported as developing fatigue in = 1 week) or gradual (developing fatigue over a period = 1 month). One 
subject described onset as between 1 week and one month and was not classified for this stratification. b Further stratification and analysis using the 
Kruskal-Wallis nonparametric test did not show different results. c Analysis performed on BMI <25 (normal) compared with >30(obese). Subjects 
considered overweight were not included in this particular analysis. Further stratification and analysis using the Kruskal-Wallis test showed no 
significant differences between the groups (results not shown.). d Illness group defined by factor analysis of symptoms followed by cluster analysis 
[4].Page 3 of 8
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The 23 CFS subjects were grouped with respect to the var-
iables listed in Table 1 and the mean differences between
their gene expression values then compared. This
approach identified 117 genes that were differentially
expressed when the CFS subjects were grouped by onset
type (Table 2). Two-class analysis did not detect any dif-
ferentially expressed genes at a false discovery rate of 5%
when comparing any other variable listed in Table 2. Both
the t-test and the Wilcoxon test results were similar to the
two-class analysis and there was considerable overlap
among the genes detected by these 3 tests for type of
fatigue onset. In total, 95/117 genes identified by two-
class analysis were detected by either t-test or Wilcoxon
test. Analysis by age, illness duration, number of CFS
symptoms, illness group and BMI identified a few differ-
entially expressed genes (Table 2), but there were no com-
mon genes across statistical tests, and no overlap with any
of the 117 genes that differentiated onset type. For this
reason, only the 117 genes identified by two-class analysis
were examined further.
Hierarchical cluster analysis of expression profiles
Figure 1 and 2 displays the two-way hierarchical cluster
analysis of the 117 genes. The majority of subjects clus-
tered according to onset type and the genes fell into two
distinct clusters. Expression of 19 of the 117 genes was
increased in the gradual compared to sudden onset group,
while the expression of the remaining 98 genes was
decreased.
Gene ontology
Figure 3 summarizes the functional classification of all
117 differentially expressed genes with respect to cluster
group. Twenty-four genes are associated with metabolism
(p < 0.01, hypergeometric probability distribution test).
Twenty of these genes were down-regulated in the gradual
onset cluster, and they were mainly involved in regulation
of glycolysis, glucose and disaccharide metabolism, oxi-
dative phosphorylation, amino acid biosynthesis, and
purine or pyrimidine metabolism. Of the 19 up-regulated
genes, some were involved in metabolism, but they were
not statistically significant. The 7 genes involved in RNA
processing were, however, statistically significant in this
group (p < 0.01, hypergeometric probability distribution
test).
Discussion
It is thought that CFS is a heterogeneous illness since a sin-
gle cause of CFS has not been identified and it is thought
that various kinds of physiologic stressors such as infec-
tion, trauma and toxins can trigger the development of
CFS in susceptible individuals. A major difficulty in iden-
tifying etiologies for CFS is that the case definition
requires a minimum duration of six months of illness. In
most studies, subjects have been ill many years, making it
difficult to detect initial disease triggers, as causal factors
may be difficult to detect or are no longer present. In addi-
tion, in many diseases, factors associated with disability
are distinct from causative factors. Biomarkers have the
potential to give clues to disease etiology as well as mode
of action.
In an attempt determine whether CFS was a single or het-
erogeneous illness, we used microarrays to profile the
expression of 3,800 genes in 23 women with CFS. We ana-
lyzed the array data using three statistical tests: 1) a pro-
gram specifically designed for the analysis of microarray
data (SAM), 2) a parametric t-test, and 3) a nonparametric
rank sum test. One class analysis by SAM failed to detect
differences in gene expression profiles of the CFS subjects
because many of the genes introduced noise into the proc-
ess, masking the differences that were evident in two-class
analysis. In the two-class analysis the only variable that
differentiated the CFS subjects was type of fatigue onset,
that is, whether the women described their fatigue as
occurring suddenly over the course of a week, or gradu-
ally, over the course of months. Different gene expression
profiles among those who describe a difference in illness
onset imply distinct etiological or triggering events, and
Table 2: Identification of differentially expressed genes in CFS subjects by clinical or epidemiologic variables.
Clinical or epidemiologic variable SAMa t-Testb (unequal variance) Wilcoxonb
Type of fatigue onset (gradual or sudden) 117 199 159
Illness group (1 or 2) 0 15 1
Age (≤50 or >50 years) 4 29 22
Body mass index (<25 or >30) 0 4 5
No. of symptoms (4 or ≥6) 0 0 0
Duration of illness (≤10 or >10) 6 19 10
a Number of genes for which false discovery rate (FDR) = 5% b Number of genes for which comparison yielded p < 0.01 c The 7 subjects with 5 
symptoms (Table 1) were excluded from the analysis of data shown in Table 2. Analysis including these subjects into either group did not 
significantly affect the outcome.Page 4 of 8
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Hierarchical clustering of the differential gene expression patterns for gradual compared with sudden onset in 
CFS subjects. Matrix of the two-dimensional hierarchical clustering of genes and CFS subjects stratified on syndrome onset. 
Each row represents the hybridization results for a single gene, and each column represents a CFS subject. Transcript levels 
that are statististically different between onset types are shown above (red) and below (green) the mean.Page 5 of 8
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disease process. All the other variables thought to be
important in characterizing and defining CFS did not have
any differentially expressed genes associated with them
when CFS subjects were grouped accordingly.
Interestingly, this is not the first time that type of fatigue
onset has distinguished people with CFS. DeLuca et al
[18] showed that CFS subjects with gradual onset tend to
develop CFS-type physical symptoms as a variant of a psy-
chiatric disorder, while CFS patients with sudden onset
may be more closely associated with a non-psychiatric eti-
ology (i.e. a viral or infectious etiology). Mawle et al. [19]
reported that CFS patients with gradual onset had more
major life events occurring in the year prior to onset than
did patients with sudden onset. In this study the 1994 CFS
research case definition [1] was strictly used in designating
CFS caseness, therefore most psychiatric conditions,
(other than Major Depressive Disorder which is comorbid
in many people with CFS, or any chronic illness) were
exclusionary. We believe that this considerably reduced
the other possible symptoms or conditions that may be
highly correlated with fatigue and could potentially con-
found our data.
Our findings of differentially expressed metabolic and
RNA processing genes make both biologic and physio-
logic sense relative to CFS. We identified differences in
purine and pyrimidine metabolism, glycolysis, oxidative
phosphorylation, and glucose metabolism. Oxidative
phosphorylation and the ATP generated by this process
are the major source of energy for the normal function of
most cells in the body. Metabolic changes are known to
take place, and in some instances drive the pathophysiol-
ogy of a number of chronic diseases. Subjects with sudden
onset CFS often describe an infectious, viral-like illness as
the initiating process. It is well-known that many RNA
processing proteins are central to the effective action of
the antiviral interferon [20]. Alterations in effective anti-
microbial responses may also explain the chronic fatigue
state.
The nature of the specimen determines the view of the dis-
ease reviewed by gene expression profiling. In CFS there
are no anatomical lesions to sample. Peripheral blood is
an accessible source of circulating cells that reflect sys-
temic changes, so it is a good starting point to profile dis-
eases that have no lesions, or lesions that are inaccessible.
However, peripheral blood mononuclear cells are them-
selves very heterogeneous, including B and T lym-
phocytes, monocytes, and natural killer cells. Changes in
gene expression could be due to changes in the cellular
composition as well as to differences in cellular activities.
However, several groups including our own, [21,22], have
surveyed the magnitude of variation in gene expression
patterns of peripheral blood and found it to be fairly lim-
ited. This study, as well as an earlier study of PBMCs in
CFS[13] indicate that the peripheral blood does detect rel-
evant gene expression differences. Fractionation of the
PBMC population may give different insights into the dis-
ease process, and will be important to further characterize
the pathophysiology of CFS.
The study must be interpreted with caution, as the
number of subjects is small and the gene profiled repre-
sent a fraction of those potentially of importance. How-
ever, these data do support the idea that CFS is a
heterogeneous illness with a biochemical basis to explain
the fatigue. Different gene expression profiles among
those who describe a difference in illness onset imply dis-
tinct etiological or triggering events, and shows that these
differences are maintained well into the disease process.
The results in this study demonstrate the utility of gene
expression profiling to characterize an illness at the bio-
logical and physiological level. This should advance the
cause for defining CFS at a molecular resulting in diagno-
sis and possible identification of causative agents.
Hierarchical clustering of the differential gene expression patterns for gradual compar  with sudden onset in CFS subj ctFigu e 2
Hierarchical clustering of the differential gene 
expression patterns for gradual compared with sud-
den onset in CFS subjects. Dendograms showing aver-
age-linkage hierarchical clustering of CFS subjects. A blue 
circle indicates a subject with a sudden onset of CFS symp-
toms, yellow indicates a gradual onset. The black circle is a 
subject whose onset was between that defined by sudden/
gradual onset.Page 6 of 8
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Although the full implication and biologic significance of
the differentially expressed genes discussed above are not
yet completely understood, the genes may serve as a plat-
form to further explore relevant mechanisms of pathogen-
esis and improve the understanding of the molecular
basis of CFS. It will be important to discover how these
differential patterns relate to non-CFS subjects and to
expand the number of genes examined. Our work shows
that microarrays are an important tool in understanding
the wide spectrum of genes likely involved in complex dis-
eases such as CFS.
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